US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Silexion Therapeutics Corp

1.61

+0.10006.62%

Post-market: 1.610.00000.00%17:03 EST

Volume:22.89K

Turnover:37.23K

Market Cap:5.03M

PE:-0.06

High:1.73

Open:1.61

Low:1.58

Close:1.51

52wk High:26.70

52wk Low:1.51

Shares:3.13M

Float Shares:2.75M

Volume Ratio:0.55

T/O Rate:0.83%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-25.2122

EPS(LYR):-395.3595

ROE:-771.23%

ROA:-77.60%

PB:0.72

PE(LYR):0.00

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Silexion Therapeutics unveils siRNA approach targeting KRAS mutations in pancreatic and other cancers

Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit

Silexion Therapeutics Publishes 2025 Shareholder Letter Highlighting Major Achievements

Silexion Therapeutics Reports Strong Preclinical Tumor Inhibition With SIL204 in KRAS-Mutated Cancers

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/SLXN"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SLXN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLXN\",,,,,undefined,":{"symbol":"SLXN","market":"US","secType":"STK","nameCN":"Silexion Therapeutics Corp","latestPrice":1.61,"timestamp":1770411600000,"preClose":1.51,"halted":0,"volume":22894,"hourTrading":{"tag":"盘后","latestPrice":1.61,"preClose":1.61,"latestTime":"17:03 EST","volume":25,"amount":41.98,"timestamp":1770415388007,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.06622516556291397,"floatShares":2753490,"shares":3126642,"eps":-25.2122,"marketStatus":"Market Closed","change":0.1,"latestTime":"02-06 16:00:00 EST","open":1.61,"high":1.7258,"low":1.58,"amount":37229.4169312,"amplitude":0.096556,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-25.2122,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":1.51,"preHourTrading":{"tag":"盘前","latestPrice":1.71,"preClose":1.51,"latestTime":"09:29 EST","volume":320,"amount":541.040032,"timestamp":1770388199013,"change":0.2,"changeRate":0.13245,"amplitude":0.086093},"postHourTrading":{"tag":"盘后","latestPrice":1.61,"preClose":1.61,"latestTime":"17:03 EST","volume":25,"amount":41.98,"timestamp":1770415388007,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.5479845349634347},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLXN\",,,,,undefined,":{"symbol":"SLXN","floatShares":2753490,"roa":"-77.60%","roe":"-771.23%","lyrEps":-395.359461,"volumeRatio":0.5479845349634347,"shares":3126642,"dividePrice":0,"high":1.7258,"amplitude":0.096556,"preClose":1.51,"low":1.58,"week52Low":1.51,"pbRate":"0.72","week52High":26.7,"institutionHeld":0,"latestPrice":1.61,"eps":-25.2122,"divideRate":0,"volume":22894,"delay":0,"ttmEps":-25.2122,"open":1.61,"prevYearClose":1.92,"prevWeekClose":1.83,"prevMonthClose":1.83,"prevQuarterClose":1.92,"fiveDayClose":1.83,"twentyDayClose":2.1,"sixtyDayClose":2.78},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SLXN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-07-29","symbol":"SLXN","defaultRemindTime":1753795800000,"type":"split","dateTimestamp":1753761600000,"forFactor":15,"toFactor":1,"ratio":15},{"market":"US","date":"2024-11-29","symbol":"SLXN","defaultRemindTime":1732890600000,"type":"split","dateTimestamp":1732856400000,"forFactor":9,"toFactor":1,"ratio":9},{"market":"US","date":"2024-08-13","symbol":"SLXN","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SLXN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SLXN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1765861200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SLXN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SLXN","date":"2026-02-06","current":-0.063858,"percent":0.255102,"low":-1.070842,"twenty":-0.606596,"median":-0.415025,"eighty":-0.12391,"high":-0.075397,"avg":-0.399536,"sd":0.253691,"marketCap":4721229},"quantilePoints":[{"date":"2025-05-02","current":-0.511745,"twenty":-0.505522,"median":-0.478123,"eighty":-0.462658,"marketCap":8414615},{"date":"2025-05-09","current":-0.508623,"twenty":-0.511745,"median":-0.504017,"eighty":-0.475134,"marketCap":8363285},{"date":"2025-05-16","current":-0.49368,"twenty":-0.511295,"median":-0.503966,"eighty":-0.488849,"marketCap":8117579},{"date":"2025-05-23","current":-0.504427,"twenty":-0.509135,"median":-0.49826,"eighty":-0.470682,"marketCap":8294286},{"date":"2025-05-30","current":-0.491275,"twenty":-0.511407,"median":-0.49826,"eighty":-0.475032,"marketCap":8078030},{"date":"2025-06-06","current":-0.471573,"twenty":-0.511407,"median":-0.49368,"eighty":-0.475196,"marketCap":7754067},{"date":"2025-06-13","current":-0.453201,"twenty":-0.509647,"median":-0.491403,"eighty":-0.471409,"marketCap":7451983},{"date":"2025-06-20","current":-0.41963,"twenty":-0.506945,"median":-0.488844,"eighty":-0.464552,"marketCap":6899984},{"date":"2025-06-27","current":-0.415025,"twenty":-0.504283,"median":-0.484008,"eighty":-0.449824,"marketCap":6824252},{"date":"2025-07-03","current":-0.415025,"twenty":-0.504048,"median":-0.478123,"eighty":-0.41963,"marketCap":6824252},{"date":"2025-07-11","current":-0.42265,"twenty":-0.503966,"median":-0.474592,"eighty":-0.417174,"marketCap":6949630},{"date":"2025-07-18","current":-0.440049,"twenty":-0.503178,"median":-0.468758,"eighty":-0.415025,"marketCap":7235727},{"date":"2025-07-25","current":-0.430889,"twenty":-0.49932,"median":-0.464408,"eighty":-0.415332,"marketCap":7085105},{"date":"2025-08-01","current":-0.509697,"twenty":-0.49932,"median":-0.462719,"eighty":-0.415332,"marketCap":8380951},{"date":"2025-08-08","current":-0.292718,"twenty":-0.495931,"median":-0.452101,"eighty":-0.414513,"marketCap":4813156},{"date":"2025-08-15","current":-0.251096,"twenty":-0.493608,"median":-0.447572,"eighty":-0.409037,"marketCap":4128768},{"date":"2025-08-22","current":-0.231991,"twenty":-0.492964,"median":-0.436237,"eighty":-0.386752,"marketCap":3814623},{"date":"2025-08-29","current":-0.263889,"twenty":-0.49148,"median":-0.430786,"eighty":-0.303498,"marketCap":4339133},{"date":"2025-09-05","current":-0.238814,"twenty":-0.491275,"median":-0.423383,"eighty":-0.280777,"marketCap":3926818},{"date":"2025-09-12","current":-0.168193,"twenty":-0.491275,"median":-0.420859,"eighty":-0.25246,"marketCap":2765601},{"date":"2025-09-19","current":-0.12316,"twenty":-0.486413,"median":-0.417583,"eighty":-0.247343,"marketCap":2025116},{"date":"2025-09-26","current":-0.128618,"twenty":-0.486106,"median":-0.415793,"eighty":-0.244955,"marketCap":2114871},{"date":"2025-10-03","current":-0.128618,"twenty":-0.484008,"median":-0.415025,"eighty":-0.242737,"marketCap":2114871},{"date":"2025-10-10","current":-0.136465,"twenty":-0.48104,"median":-0.413413,"eighty":-0.231991,"marketCap":2243896},{"date":"2025-10-17","current":-0.121454,"twenty":-0.478123,"median":-0.409651,"eighty":-0.138853,"marketCap":1997067},{"date":"2025-10-24","current":-0.114972,"twenty":-0.478123,"median":-0.401489,"eighty":-0.132201,"marketCap":1890482},{"date":"2025-10-31","current":-0.112584,"twenty":-0.477611,"median":-0.386196,"eighty":-0.129301,"marketCap":1851214},{"date":"2025-11-07","current":-0.097914,"twenty":-0.471573,"median":-0.312505,"eighty":-0.127936,"marketCap":1609995},{"date":"2025-11-14","current":-0.097914,"twenty":-0.471163,"median":-0.292718,"eighty":-0.123842,"marketCap":1609995},{"date":"2025-11-21","current":-0.080173,"twenty":-0.468758,"median":-0.272333,"eighty":-0.121795,"marketCap":1318288},{"date":"2025-11-28","current":-0.096549,"twenty":-0.467039,"median":-0.257237,"eighty":-0.120362,"marketCap":1587556},{"date":"2025-12-05","current":-1.070842,"twenty":-0.471245,"median":-0.259284,"eighty":-0.119953,"marketCap":9902075},{"date":"2025-12-12","current":-1.0279,"twenty":-0.478706,"median":-0.282158,"eighty":-0.120362,"marketCap":9504991},{"date":"2025-12-19","current":-0.821644,"twenty":-0.486167,"median":-0.30227,"eighty":-0.120704,"marketCap":7597740},{"date":"2025-12-26","current":-0.797975,"twenty":-0.491377,"median":-0.316599,"eighty":-0.121181,"marketCap":7378875},{"date":"2026-01-02","current":-0.6492,"twenty":-0.495368,"median":-0.386196,"eighty":-0.12159,"marketCap":6003152},{"date":"2026-01-09","current":-0.710063,"twenty":-0.504027,"median":-0.401489,"eighty":-0.122205,"marketCap":6565948},{"date":"2026-01-16","current":-0.825025,"twenty":-0.510588,"median":-0.409651,"eighty":-0.122955,"marketCap":7629006},{"date":"2026-01-23","current":-0.726969,"twenty":-0.515839,"median":-0.412313,"eighty":-0.12316,"marketCap":6722280},{"date":"2026-01-30","current":-0.662725,"twenty":-0.574408,"median":-0.414769,"eighty":-0.123296,"marketCap":6128218},{"date":"2026-02-06","current":-0.510569,"twenty":-0.606596,"median":-0.415025,"eighty":-0.12391,"marketCap":4721229}],"updateTime":1770554203979},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SLXN\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2608877601","title":"Silexion Therapeutics unveils siRNA approach targeting KRAS mutations in pancreatic and other cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2608877601","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608877601?lang=en_us&edition=fundamental","pubTime":"2026-02-03 22:33","pubTimestamp":1770129232,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp. has provided an update on its lead product, SIL204, a first-in-class, isoform-selective pan-KRAS silencer designed for targeted cancer therapy. The presentation highlights the use of siRNA technology to silence mutated KRAS, the most common oncogenic driver in several human cancers, including pancreatic, colorectal, and non-squamous non-small cell lung cancer. SIL204 is engineered for dual administration—systemic and intratumoral—to address both primary tumors and metastatic disease, particularly in pancreatic ductal adenocarcinoma . The company reports that SIL204 binds extensively to low-density lipoproteins , exploiting the increased LDL receptor expression in pancreatic cancer cells to enhance targeted delivery. Preclinical and Phase 2 clinical data from earlier siRNA candidates, as well as the development plan for SIL204, are included in the presentation. You can access the full presentation through the link below.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL6S6KT5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"2605107703","title":"Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2605107703","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605107703?lang=en_us&edition=fundamental","pubTime":"2026-01-21 21:30","pubTimestamp":1769002230,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp., a clinical-stage biotechnology company focused on oncology, will attend the 7th RNAi-Based Therapeutics Summit, taking place January 27-29, 2026, in Boston, MA. Company management, including CEO Ilan Hadar, will participate in the event, and Silexion will also be an official partner of the summit. Silexion is developing SIL204, a next-generation siRNA therapy targeting mutated KRAS oncogenes, with plans to initiate a Phase 2/3 clinical study in locally advanced pancreatic cancer in mid-2026. Interested parties can arrange one-on-one meetings with Silexion management through the company’s investor relations representatives.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nNDL7ykQd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BKPKM429.USD","IE00BGHQF748.EUR","BK4112","SG9999014039.USD","SG9999014013.SGD","BK4588","SLXN","LU2210150020.SGD","LU2095319765.USD","BK4139","SG9999014021.USD","IE00B64PRP62.GBP","NDAQ","LU2210149790.SGD","IE00B3QW5Z07.USD","LU0314104364.USD","SG9999014005.SGD"],"gpt_icon":0},{"id":"2601890363","title":"Silexion Therapeutics Publishes 2025 Shareholder Letter Highlighting Major Achievements","url":"https://stock-news.laohu8.com/highlight/detail?id=2601890363","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601890363?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:25","pubTimestamp":1767705917,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp. has published a shareholder letter from Chairman and Chief Executive Officer Ilan Hadar. The letter highlights achievements in 2025, including positive preclinical data for SIL204, completion of regulatory toxicology studies, and positive feedback from Germany’s Federal Institute for Drugs and Medical Devices regarding Phase 2/3 trial design. The letter also outlines plans to initiate a Phase 2/3 clinical trial in locally advanced pancreatic cancer in the first half of 2026 and discusses expected milestones for the upcoming year. The full letter can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL5TLjpW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"2601560892","title":"Silexion Therapeutics Reports Strong Preclinical Tumor Inhibition With SIL204 in KRAS-Mutated Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2601560892","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601560892?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:30","pubTimestamp":1767702609,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp. has announced significant preclinical research results for its lead RNA interference  therapy, SIL204, targeting KRAS-driven cancers. The company reported that SIL204 demonstrated substantial tumor inhibition in human KRAS-mutated cancer cell line models, including pancreatic, colorectal, and lung cancers. These findings, achieved in 2025, have not yet been presented in human clinical trials, which are scheduled to begin in the first half of 2026. Silexion also completed regulatory toxicology studies and received positive feedback from Germany's Federal Institute for Drugs and Medical Devices  on its Phase 2/3 trial design, paving the way for the upcoming clinical trial of SIL204 in locally advanced pancreatic cancer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL3cF3Gk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","SLXN","IE00B64PRP62.GBP","SG9999014013.SGD","BK4139","BK4112","IE00BGHQF748.EUR","NDAQ","BK4585","LU2210150020.SGD","SG9999014005.SGD","BK4588","SG9999014039.USD","LU2210149790.SGD","LU0314104364.USD","SG9999014021.USD","IE00B3QW5Z07.USD","LU2095319765.USD"],"gpt_icon":0}],"pageSize":4,"totalPage":13,"pageCount":1,"totalSize":51,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/SLXN\",params:#limit:6,delay:false,,,undefined,":[]}}